LabConnect and Kits4Life Join Forces to Minimize Clinical Trial Waste

LabConnect Partners with Kits4Life

In a significant move towards environmental stewardship in the realm of clinical research, LabConnect has officially announced its partnership with Kits4Life. This initiative, powered by the MedSurplus Alliance, aims to tackle the critical issue of waste generated during clinical trials, specifically unused and expired specimen collection kits.

With the growing emphasis on sustainability across various sectors, LabConnect is reinforcing its commitment to corporate social responsibility by aligning its efforts with Kits4Life. This collaboration is part of LabConnect's comprehensive Environmental, Social, and Governance (ESG) strategy, demonstrating its leadership as a responsible provider of central laboratory services.

The clinical trial process, essential for developing groundbreaking therapies, often leads to substantial material waste, including high-quality medical materials contained in unused kits. Recognizing this challenge, LabConnect is dedicated to identifying and managing kits eligible for donation. By doing so, the organization aims to not only minimize landfill waste but also enhance global health equity by redirecting these resources to communities with pressing healthcare needs.

Julia Tarasenko, Chief Commercial Strategy Officer at LabConnect, expressed her enthusiasm for the partnership, stating, "We are excited to partner with Kits4Life as a framework for recovering surplus clinical trial kits and ensuring they are ethically and safely donated to organizations. This is a critical step towards not just reducing waste, but actively contributing to better healthcare access worldwide."

This partnership highlights LabConnect's broader mission of transforming clinical trials into a sustainable and inclusive global enterprise. The company is proactively addressing the environmental impact of clinical research by minimizing carbon footprints, promoting ethical sourcing, and engaging with communities. By integrating environmental and social responsibility throughout the entire lifecycle of clinical research, LabConnect is paving the way for a more sustainable future in the industry.

LabConnect's commitment to this cause emphasizes that sustainability does not have to conflict with scientific innovation. Instead, the two can complement each other, leading to a future where environmental responsibility is a fundamental aspect of developing breakthrough therapies. As noted by Tarasenko, "As the clinical research industry evolves, partnerships like this help chart a path forward where environmental responsibility and breakthrough therapies go hand in hand."

LabConnect, renowned for its expertise in providing Central Laboratory Services, FSP, Scientific Consulting, and Data Integration, offers comprehensive support for complex studies like immuno-oncology, cell and gene therapies, as well as rare diseases. The company's unique combination of cutting-edge technology, access to established and emerging markets, and specialized testing capabilities makes it a reliable partner for drug development companies seeking central laboratory service solutions.

For more information about LabConnect and its services, visit www.labconnect.com and follow them on LinkedIn to stay updated on their latest initiatives and advancements.